{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:57:47Z","timestamp":1794502667026,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["ZonMw VIDI 09150172010035"],"award-info":[{"award-number":["ZonMw VIDI 09150172010035"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["ZonMw VIDI 09150172010035"],"award-info":[{"award-number":["ZonMw VIDI 09150172010035"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Genetically attenuated parasites (GAPs) that arrest during liver stage development have shown significant potential as malaria vaccines. Compared to <jats:italic>Plasmodium falciparum<\/jats:italic> GAPs that arrest after 24\u201348\u2009h (early-arresters), parasites arresting after 6\u20137 days (late-arresters) have shown superior efficacy, highlighting the importance of liver stage immunity in promoting sterile protection. Here, we describe GAPs tested in humans and the pre-clinical research that led to their creation. We discuss safety and efficacy of existing GAPs with particular focus on their large-scale implementation as malaria vaccines.<\/jats:p>","DOI":"10.1038\/s41541-025-01265-z","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:35:57Z","timestamp":1759923357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The path from early- to late-liver stage arresting genetically attenuated parasites as a malaria vaccination strategy"],"prefix":"10.1038","volume":"10","author":[{"given":"O.A.C.","family":"Lamers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.D.","family":"Franke-Fayard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roestenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.M.","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"H Tinto","year":"2015","unstructured":"Tinto, H. et al. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"1265_CR2","unstructured":"Organization, W. H. Malaria vaccines (RTS,S and R21), https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/q-a-on-rts-s-malaria-vaccine (2024)."},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4269\/ajtmh.22-0544a","volume":"107","author":"A Birkett","year":"2022","unstructured":"Birkett, A., Miller, R. S. & Soisson, L. A. The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule. Am. J. Trop. Med Hyg. 107, 1356\u20131356 (2022).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"1265_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00130-7","volume":"5","author":"L Kurtovic","year":"2024","unstructured":"Kurtovic, L. et al. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial. Lancet Microbe 5, 100898 (2024).","journal-title":"Lancet Microbe"},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2012.08.045","volume":"30","author":"E Shim","year":"2012","unstructured":"Shim, E. & Galvani, A. P. Distinguishing vaccine efficacy and effectiveness. Vaccine 30, 6700\u20136705 (2012).","journal-title":"Vaccine"},{"key":"1265_CR6","unstructured":"Vaccine efficacy, effectiveness and protection, https:\/\/www.who.int\/news-room\/feature-stories\/detail\/vaccine-efficacy-effectiveness-and-protection (2025)."},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"1265_CR9","unstructured":"WHO. (2021)."},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s44321-024-00131-0","volume":"16","author":"D Moita","year":"2024","unstructured":"Moita, D. & Prudencio, M. Whole-sporozoite malaria vaccines: where we are, where we are going. EMBO Mol. Med 16, 2279\u20132289 (2024).","journal-title":"EMBO Mol. Med"},{"key":"1265_CR11","doi-asserted-by":"publisher","unstructured":"Stanisic, D. I., McCarthy, J. S. & Good, M. F. Controlled Human Malaria Infection: Applications, Advances, and Challenges. Infect Immun 86 https:\/\/doi.org\/10.1128\/IAI.00479-17 (2018).","DOI":"10.1128\/IAI.00479-17"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, 1\u201314 (2017).","journal-title":"JCI Insight"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo, S. A. et al. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clin. Infect. Dis. 71, 2849\u20132857 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.21-0942","volume":"106","author":"SA Jongo","year":"2022","unstructured":"Jongo, S. A. et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. Am. J. Trop. Med Hyg. 106, 1215\u20131226 (2022).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg, M. et al. Protection against a Malaria Challenge by Sporozoite Inoculation. N. Engl. J. Med 361, 468\u2013477 (2009).","journal-title":"N. Engl. J. Med"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordmuller","year":"2017","unstructured":"Mordmuller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.copbio.2012.04.003","volume":"23","author":"SM Khan","year":"2012","unstructured":"Khan, S. M., Janse, C. J., Kappe, S. H. & Mikolajczak, S. A. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 23, 908\u2013916 (2012).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nature03188","volume":"433","author":"AK Mueller","year":"2005","unstructured":"Mueller, A. K., Labaied, M., Kappe, S. H. I. & Matuschewski, K. Genetically modified parasites as a protective experimental malaria vaccine. Nature 433, 164\u2013167 (2005).","journal-title":"Nature"},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1073\/pnas.0408442102","volume":"102","author":"AK Mueller","year":"2005","unstructured":"Mueller, A. K. et al. Liver stage developmental arrest by depletion of a protein at the parasite-host interface. P Natl Acad. Sci. USA 102, 3022\u20133027 (2005).","journal-title":"P Natl Acad. Sci. USA"},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1046\/j.1365-2958.2003.03909.x","volume":"51","author":"K Kaiser","year":"2004","unstructured":"Kaiser, K., Matuschewski, K., Camargo, N., Ross, J. & Kappe, S. H. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol. Microbiol 51, 1221\u20131232 (2004).","journal-title":"Mol. Microbiol"},{"key":"1265_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12936-6","volume":"10","author":"SE Lindner","year":"2019","unstructured":"Lindner, S. E. et al. Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites. Nat. Commun. 10, 4964 (2019).","journal-title":"Nat. Commun."},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1086\/519742","volume":"196","author":"AS Tarun","year":"2007","unstructured":"Tarun, A. S. et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J. Infect. Dis. 196, 608\u2013616 (2007).","journal-title":"J. Infect. Dis."},{"key":"1265_CR24","first-page":"90","volume":"77","author":"O Jobe","year":"2007","unstructured":"Jobe, O. et al. Genetically-attenuated liver-stages induce sterile protracted protection that is mediated by MHC class I-dependent IFN-\u03b3 producing CD8+ T cells. Am. J. Trop. Med Hyg. 77, 90\u201390 (2007).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1128\/EC.00336-09","volume":"9","author":"DC Mackellar","year":"2010","unstructured":"Mackellar, D. C. et al. Plasmodium falciparum PF10_0164 (ETRAMP10.3) is an essential parasitophorous vacuole and exported protein in blood stages. Eukaryot. Cell 9, 784\u2013794 (2010).","journal-title":"Eukaryot. Cell"},{"key":"1265_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104224","volume":"25","author":"D Goswami","year":"2022","unstructured":"Goswami, D. et al. A Plasmodium falciparum ATP-binding cassette transporter is essential for liver stage entry into schizogony. Iscience 25, 104224 (2022).","journal-title":"Iscience"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1462-5822.2008.01270.x","volume":"11","author":"AM Vaughan","year":"2009","unstructured":"Vaughan, A. M. et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11, 506\u2013520 (2009).","journal-title":"Cell Microbiol"},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.chom.2011.05.008","volume":"9","author":"NS Butler","year":"2011","unstructured":"Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451\u2013462 (2011).","journal-title":"Cell Host Microbe"},{"key":"1265_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.chom.2008.11.001","volume":"4","author":"M Yu","year":"2008","unstructured":"Yu, M. et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567\u2013578 (2008).","journal-title":"Cell Host Microbe"},{"key":"1265_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1128\/EC.00264-13","volume":"13","author":"BC van Schaijk","year":"2014","unstructured":"van Schaijk, B. C. et al. Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot. Cell 13, 550\u2013559 (2014).","journal-title":"Eukaryot. Cell"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1128\/IAI.00225-07","volume":"75","author":"M Labaied","year":"2007","unstructured":"Labaied, M. et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 75, 3758\u20133768 (2007).","journal-title":"Infect. Immun."},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"e3549","DOI":"10.1371\/journal.pone.0003549","volume":"3","author":"BC van Schaijk","year":"2008","unstructured":"van Schaijk, B. C. et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 3, e3549 (2008).","journal-title":"PLoS One"},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"12194","DOI":"10.1073\/pnas.0500925102","volume":"102","author":"MR van Dijk","year":"2005","unstructured":"van Dijk, M. R. et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl Acad. Sci. USA 102, 12194\u201312199 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1016\/j.vaccine.2012.02.010","volume":"30","author":"T Annoura","year":"2012","unstructured":"Annoura, T. et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 30, 2662\u20132670 (2012).","journal-title":"Vaccine"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2013.08.007","volume":"31","author":"M Spring","year":"2013","unstructured":"Spring, M. et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31, 4975\u20134983 (2013).","journal-title":"Vaccine"},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"13004","DOI":"10.1073\/pnas.0906387106","volume":"106","author":"KM VanBuskirk","year":"2009","unstructured":"VanBuskirk, K. M. et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl Acad. Sci. USA 106, 13004\u201313009 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijpara.2010.08.001","volume":"41","author":"MT O\u2019Neill","year":"2011","unstructured":"O\u2019Neill, M. T., Phuong, T., Healer, J., Richard, D. & Cowman, A. F. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J. Parasitol. 41, 117\u2013123 (2011).","journal-title":"Int J. Parasitol."},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/mt.2014.85","volume":"22","author":"SA Mikolajczak","year":"2014","unstructured":"Mikolajczak, S. A. et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol. Ther. 22, 1707\u20131715 (2014).","journal-title":"Mol. Ther."},{"key":"1265_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-2958.2010.07497.x","volume":"79","author":"ASI Aly","year":"2011","unstructured":"Aly, A. S. I., Lindner, S. E., MacKellar, D. C., Peng, X. X. & Kappe, S. H. I. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol. Microbiol 79, 929\u2013939 (2011).","journal-title":"Mol. Microbiol"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2958.2008.06271.x","volume":"69","author":"ASI Aly","year":"2008","unstructured":"Aly, A. S. I. et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol 69, 152\u2013163 (2008).","journal-title":"Mol. Microbiol"},{"key":"1265_CR41","doi-asserted-by":"publisher","unstructured":"Kublin, J. G. et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med 9 https:\/\/doi.org\/10.1126\/scitranslmed.aad9099 (2017).","DOI":"10.1126\/scitranslmed.aad9099"},{"key":"1265_CR42","doi-asserted-by":"publisher","unstructured":"Murphy, S. C. et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection. Sci Transl Med 14 https:\/\/doi.org\/10.1126\/scitranslmed.abn9709 (2022).","DOI":"10.1126\/scitranslmed.abn9709"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1096\/fj.13-241570","volume":"28","author":"T Annoura","year":"2014","unstructured":"Annoura, T. et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. Faseb J. 28, 2158\u20132170 (2014).","journal-title":"Faseb J."},{"key":"1265_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.03582","volume":"3","author":"BC van Schaijk","year":"2014","unstructured":"van Schaijk, B. C. et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9\/slarp gene-deficient sporozoites. Elife 3, 1\u201318 (2014).","journal-title":"Elife"},{"key":"1265_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med 12, 1\u20139 (2020).","journal-title":"Sci. Transl. Med"},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S1473-3099(20)30020-7","volume":"20","author":"MCC Langenberg","year":"2020","unstructured":"Langenberg, M. C. C., Dekkers, O. M. & Roestenberg, M. Are placebo controls necessary in controlled human infection trials for vaccines?. Lancet Infect. Dis. 20, e69\u2013e74 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1128\/IAI.01417-15","volume":"84","author":"DA Dankwa","year":"2016","unstructured":"Dankwa, D. A., Davis, M. J., Kappe, S. H. I. & Vaughan, A. M. A Plasmodium yoelii Mei2-Like RNA Binding Protein Is Essential for Completion of Liver Stage Schizogony. Infect. Immun. 84, 1336\u20131345 (2016).","journal-title":"Infect. Immun."},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00558-x","volume":"7","author":"B Franke-Fayard","year":"2022","unstructured":"Franke-Fayard, B. et al. Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver. Npj Vaccines 7, 1\u201317 (2022).","journal-title":"Npj Vaccines"},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/IAI.00088-18","volume":"86","author":"AM Vaughan","year":"2018","unstructured":"Vaughan, A. M. et al. A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice. Infect. Immun. 86, 1\u201318 (2018).","journal-title":"Infect. Immun."},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.135589","volume":"5","author":"D Goswami","year":"2020","unstructured":"Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, 1\u201319 (2020).","journal-title":"JCI Insight"},{"key":"1265_CR51","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1056\/NEJMoa2313892","volume":"391","author":"OAC Lamers","year":"2024","unstructured":"Lamers, O. A. C. et al. Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite. N. Engl. J. Med 391, 1913\u20131923 (2024).","journal-title":"N. Engl. J. Med"},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-024-03347-2","volume":"31","author":"GVT Roozen","year":"2025","unstructured":"Roozen, G. V. T. et al. Single immunization with genetically attenuated Pf\u2206mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat. Med 31, 218\u2013222 (2025).","journal-title":"Nat. Med"},{"key":"1265_CR53","doi-asserted-by":"publisher","unstructured":"Goswami, D. et al. A conserved nuclear protein is critical for late liver stage development. Commun Biol 7 https:\/\/doi.org\/10.1038\/s42003-024-07063-y (2024).","DOI":"10.1038\/s42003-024-07063-y"},{"key":"1265_CR54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s44321-024-00057-7","volume":"16","author":"D Goswami","year":"2024","unstructured":"Goswami, D. et al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol. Med 16, 723\u2013754 (2024).","journal-title":"EMBO Mol. Med"},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"1265_CR56","doi-asserted-by":"publisher","unstructured":"Mura, M. et al. Immunoprofiling Identifies Functional B and T Cell Subsets Induced by an Attenuated Whole Parasite Malaria Vaccine as Correlates of Sterile Immunity. Vaccines (Basel) 10 https:\/\/doi.org\/10.3390\/vaccines10010124 (2022).","DOI":"10.3390\/vaccines10010124"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).","journal-title":"PLoS Pathog."},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/infdis\/jiu293","volume":"210","author":"EM Bijker","year":"2014","unstructured":"Bijker, E. M. et al. Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites. J. Infect. Dis. 210, 1605\u20131615 (2014).","journal-title":"J. Infect. Dis."},{"key":"1265_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112589","volume":"28","author":"E Colstrup","year":"2025","unstructured":"Colstrup, E. et al. Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans. iScience 28, 112589 (2025).","journal-title":"iScience"},{"key":"1265_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2021.104807","volume":"4-5","author":"KJ Rogers","year":"2021","unstructured":"Rogers, K. J., Vijay, R. & Butler, N. S. Anti-malarial humoral immunity: the long and short of it. Microbes Infect. 4-5, 104807 (2021).","journal-title":"Microbes Infect."},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.pt.2024.10.017","volume":"40","author":"M Singer","year":"2024","unstructured":"Singer, M., Kanatani, S., Castillo, S. G., Frischknecht, F. & Sinnis, P. The Plasmodium circumsporozoite protein. Trends Parasitol. 40, 1124\u20131134 (2024).","journal-title":"Trends Parasitol."},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.pt.2023.07.002","volume":"39","author":"DS Guttery","year":"2023","unstructured":"Guttery, D. S., Zeeshan, M., Holder, A. A., Tromer, E. C. & Tewari, R. Meiosis in Plasmodium: how does it work?. Trends Parasitol. 39, 812\u2013821 (2023).","journal-title":"Trends Parasitol."},{"key":"1265_CR63","doi-asserted-by":"publisher","unstructured":"Midtvedt, T. Antibiotic resistance and genetically modified plants. Microb Ecol Health Dis 25 https:\/\/doi.org\/10.3402\/mehd.v25.25918 (2014).","DOI":"10.3402\/mehd.v25.25918"},{"key":"1265_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2021.100432","volume":"42","author":"F Sakurai","year":"2022","unstructured":"Sakurai, F., Tachibana, M. & Mizuguchi, H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 42, 100432 (2022).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"1265_CR65","doi-asserted-by":"publisher","unstructured":"van Dorst, M. et al. Immunological factors linked to geographical variation in vaccine responses. Nat Rev Immunol https:\/\/doi.org\/10.1038\/s41577-023-00941-2 (2023).","DOI":"10.1038\/s41577-023-00941-2"},{"key":"1265_CR66","doi-asserted-by":"publisher","unstructured":"Reuling, I. J. et al. An open-label phase 1\/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci Transl Med 12 https:\/\/doi.org\/10.1126\/scitranslmed.aay2 (2020).","DOI":"10.1126\/scitranslmed.aay2"},{"key":"1265_CR67","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1073\/pnas.97.13.6994","volume":"97","author":"SM Rich","year":"2000","unstructured":"Rich, S. M. & Ayala, F. J. Population structure and recent evolution of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 97, 6994\u20137001 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1265_CR68","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0140-6736(11)60360-7","volume":"377","author":"M Roestenberg","year":"2011","unstructured":"Roestenberg, M. et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377, 1770\u20131776 (2011).","journal-title":"Lancet"},{"key":"1265_CR69","doi-asserted-by":"publisher","unstructured":"Blight, J. et al. Dissection-independent production of Plasmodium sporozoites from whole mosquitoes. Life Sci Alliance 4 https:\/\/doi.org\/10.26508\/lsa.202101094 (2021).","DOI":"10.26508\/lsa.202101094"},{"key":"1265_CR70","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41586-022-05466-7","volume":"612","author":"AG Eappen","year":"2022","unstructured":"Eappen, A. G. et al. In vitro production of infectious Plasmodium falciparum sporozoites. Nature 612, 534\u2013539 (2022).","journal-title":"Nature"},{"key":"1265_CR71","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","volume":"22","author":"TL Richie","year":"2023","unstructured":"Richie, T. L. et al. Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria. Expert Rev. Vaccines 22, 964\u20131007 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med 22, 614\u2013623 (2016).","journal-title":"Nat. Med"},{"key":"1265_CR73","unstructured":"Organization, W. H. (ed World Health Organization) (Geneva, 2022)."},{"key":"1265_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914598","volume":"13","author":"K Pohl","year":"2022","unstructured":"Pohl, K. & Cockburn, I. A. Innate immunity to malaria: The good, the bad and the unknown. Front Immunol. 13, 914598 (2022).","journal-title":"Front Immunol."},{"key":"1265_CR75","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00281-012-0345-5","volume":"34","author":"P Sinnis","year":"2012","unstructured":"Sinnis, P. & Zavala, F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 34, 787\u2013792 (2012).","journal-title":"Semin Immunopathol."},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nm1628","volume":"13","author":"S Chakravarty","year":"2007","unstructured":"Chakravarty, S. et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med 13, 1035\u20131041 (2007).","journal-title":"Nat. Med"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01265-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01265-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01265-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:03:27Z","timestamp":1759928607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01265-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01265-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}